TAR-200 Monotherapy Outperforms Combination Therapy in SunRISe-1

Comparative findings presented at ESMO 2024 from the SunRISe-1 trial distinctly showed that TAR-200 monotherapy substantially outperformed its combination with the PD-1 inhibitor cetrelimab. TAR-200 monotherapy achieved an impressive complete response rate of 83.5%, significantly higher than the 67.9% seen in the combination group. Furthermore, monotherapy exhibited better tolerability, showcasing a lower adverse event profile compared to the combination regimen. Conversely, cetrelimab alone achieved a notably lower complete response rate of only 46%, reinforcing TAR-200’s strong standalone clinical efficacy. This finding suggests that TAR-200 monotherapy provides not only robust clinical effectiveness but also simpler treatment regimens, minimizing patient burden and healthcare resource utilization.

Citation: ESMO Daily Reporter, 2024. Available at: https://dailyreporter.esmo.org

Implication: TAR-200 monotherapy's superior efficacy and safety may simplify clinical protocols and enhance patient outcomes and compliance.